Information Provided By:
Fly News Breaks for November 21, 2019
VKTX
Nov 21, 2019 | 10:30 EDT
SunTrust analyst Joon Lee said he sees "nothing concerning" in the ClinicalTrials.gov posting for Viking Therapeutics' VOYAGER study, stating that the inclusion criteria is "minimally restrictive." He also heard some investors voice concern that the study may only be six months, but he spoke with the company's CEO, who confirmed it will be a 12 month study. The analyst, who thinks confusion about the study may have lead to share weakness in recent days, reiterates a Buy rating on Viking shares.
News For VKTX From the Last 2 Days
There are no results for your query VKTX